Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Meridian Bioscience, Inc.

http://www.meridianbioscience.com

Latest From Meridian Bioscience, Inc.

Another COVID-19 Diagnostic Impacted By Omicron Variant

The Revogene SARS-CoV-2 test from Meridian Bioscience could give false-negative results because of the latest coronavirus variant. The good news is that the diagnostic hasn’t been distributed in the US, the FDA says.

Coronavirus COVID-19 Diagnostics

MDR/IVDR Survey: Most Manufacturers Ready To Yank Some Legacy Products From EU Market; Hiring Up At Firms

The impending implementation of the EU's new Medical Device and IVD Regulations will cause most firms to pull select legacy devices and in vitro diagnostics from the EU market, a survey of 169 quality and/or regulatory professionals finds. The survey also revealed that companies are in hiring mode as the compliance dates for both regulations approach. Quality and regulatory officials from Abbott Laboratories and Meridian Bioscience weigh in.

Policy Regulation

Severe Asthma Market Snapshot: A Competitive Therapy Area That Will Test Payers' Influence

Several biologic drugs are now available for the 10% of asthma patients with severe uncontrolled disease, and Dupixent could join them later this year, setting the therapy area up for a competitive showdown.

Market Snapshot Respiratory

Fast And Furious: How The First-To-Market Advantage Is Shrinking

The competitive dynamics in the pharmaceutical sector appear to be intensifying, with second- and third-to-market drugs reaching the market faster behind first-in-class drugs. That's putting more pressure on new drug launches and impacting drug pricing and rebating strategies.

Launches Market Access
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Other Names / Subsidiaries
    • Bioline
    • Exalenz Bioscience Ltd.
    • GenePOC Inc.
    • Magellan Biosciences, Inc., Magellan Diagnostics
    • Meridian Diagnostics
UsernamePublicRestriction

Register